Fulgent GeneticsFRA:7F0 -0.55%64 Buyback Yield % is 8.04 as of Jul. 05, 2026, which is 373% above its 10-year median of 1.70. GuruFocus rates FRA:7F0 with a GF Score™ of 64/100 and a GF Value™ of €20.87. The stock has 4 warning signs investors should review. Among 90 Medical Diagnostics & Research companies, Fulgent Genetics ranks better than 98.89% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Fulgent Genetics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7F0 vs MYGN, CSTL, BDSX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (FRA:7F0) has a Buyback Yield % of 8.04 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Fulgent Genetics and its competitors. This is 373% above median its historical median of 1.70. According to the industry distribution chart, Fulgent Genetics ranks #1 out of 90 companies in the Medical Diagnostics & Research industry, placing it in the top 1.1%.
Is Fulgent Genetics' Buyback Yield % too high?
Fulgent Genetics' current Buyback Yield % of 8.04 is 373% above median its 10-year median of 1.70. Based on the distribution chart, Fulgent Genetics ranks #1 out of 90 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fulgent Genetics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Buyback Yield % compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #1 out of 90 companies for Buyback Yield %. This places Fulgent Genetics in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Buyback Yield % is 8.04, which is 373% above median its own 10-year median of 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Fulgent Genetics (FRA:7F0) has a current Buyback Yield % of 8.04. The stock's GF Value™ is €20.87, compared to a current price of €18.10 — trading 13.3% below its estimated fair value. The current Buyback Yield % is 8.04, which is 373% above median its 10-year median of 1.70. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Fulgent Genetics (FRA:7F0), the current Buyback Yield % is 8.04 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FRA:7F0) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of €18.10 is trading 13.3% below its estimated GF Value™ of €20.87.
Key valuation signals for FRA:7F0:
Buyback Yield %: 8.04 (373% above median its 10-year median of 1.70)
GF Value™: €20.87 vs. price of €18.10 (13.3% below fair value)
No single metric tells the full story. See the FRA:7F0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score
Get the complete analysis for FRA:7F0
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7F0 has been successfully added to your 
